Lucerastat
Lucerastat (NBDGJ) is an orally administered glucosylceramide synthase (GCS) inhibitor investigated for Fabry disease. By blocking a key step in sphingolipid biosynthesis, it reduces the accumulation of pathogenic substrates, as demonstrated in relevant cellular and animal models of lysosomal storage disorders.
Product Specifications
CAS Number
141206-42-0
Field of Research
Metabolism Research
Purity
98.00% (May vary between batches)
Smiles
C (CCC) N1[C@H] (CO) [C@H] (O) [C@H] (O) [C@@H] (O) C1
Molecular Formula
C10H21NO4
Molecular Weight
219.28
Storage Conditions
-20°C
Notes
For research use only.
More Discoveries
Explore Other Products
Browse additional items from our catalog
034982-ML650 100 µL
EIF1AY, NT (EIF1AY, Eukaryotic translation initiation factor 1A, Y-chromosomal, Eukaryotic translation initiation factor 4C) (MaxLight 650) discontinued
Sign In for Pricing
View Details 
TP-1010-4 20 g / 1 L
AccuBeadTM Silica Coated Magnetic Bead, Irregular Fine, 20 g/1 L
Sign In for Pricing
View Details 
MBS3905360-01 0.01 mg
Rabbit anti-TMED10/TMP21 Antibody, Affinity Purified
Sign In for Pricing
View Details MBS3905360-02 0.1 mg
Rabbit anti-TMED10/TMP21 Antibody, Affinity Purified
Sign In for Pricing
View Details MBS3905360-03 5x 0.01 mg
Rabbit anti-TMED10/TMP21 Antibody, Affinity Purified
Sign In for Pricing
View Details MBS3905360-04 5x 0.1 mg
Rabbit anti-TMED10/TMP21 Antibody, Affinity Purified
Sign In for Pricing
View Details